The Effect of Epstein-Barr Virus Latent Membrane Protein 2 Expression on the Kinetics of Early B Cell Infection

PLoS ONE

Volumn 8, Issue 1, 2013, Pages

  Wasil, Laura R ^a   Tomaszewski, Monica J ^a   Hoji, Aki ^a   Rowe, David T ^a  

^a UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMEDIATE EARLY PROTEIN BZLF1; LATENT MEMBRANE PROTEIN 1; LATENT MEMBRANE PROTEIN 2; LATENT MEMBRANE PROTEIN 2A; LATENT MEMBRANE PROTEIN 2B; UNCLASSIFIED DRUG; VIRUS DNA;

APOPTOSIS; ARTICLE; B LYMPHOCYTE; B LYMPHOCYTE ACTIVATION; CELL GROWTH; CELL KINETICS; CELL PROLIFERATION; EPSTEIN BARR VIRUS; EPSTEIN BARR VIRUS INFECTION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; IN VITRO STUDY; LMP2A GENE; LMP2B GENE; PROTEIN EXPRESSION; PROTEIN FUNCTION; VIRUS GENE; VIRUS LATENCY;

APOPTOSIS; B-LYMPHOCYTES; CELL PROLIFERATION; CELL SURVIVAL; CELL TRANSFORMATION, VIRAL; GENE EXPRESSION REGULATION, VIRAL; GENE KNOCKOUT TECHNIQUES; HEK293 CELLS; HERPESVIRUS 4, HUMAN; HUMANS; KINETICS; LYMPHOCYTE ACTIVATION; RNA, MESSENGER; RNA, VIRAL; TIME FACTORS; TRANS-ACTIVATORS; VIRAL MATRIX PROTEINS; VIRUS LATENCY;

HUMAN HERPESVIRUS 4;

EID: 84872184364     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0054010     Document Type: Article

References (74)

1. Rickinson AB, Kieff E (2007) Epstein-Barr virus. In: Knipe DM, Howley PM, Griffin DE, Lamb RA, Martin MA, et al., editors. Fields Virology. 5th ed. Philadelphia: Lippincott, Williams & Wilkins. 2655-2700.
2. Thorley-Lawson DA, (2001) Epstein-Barr virus: exploiting the immune system. Nature reviews Immunology 1: 75-82.
3. Young LS, Murray PG, (2003) Epstein-Barr virus and oncogenesis: from latent genes to tumours. Oncogene 22: 5108-5121.
4. Dolcetti R, (2007) B lymphocytes and Epstein-Barr virus: the lesson of post-transplant lymphoproliferative disorders. Autoimmun Rev 7: 96-101.
5. Krenauer A, Moll A, Ponisch W, Schmitz N, Niedobitek G, et al. (2010) EBV-associated post-transplantation B-cell lymphoproliferative disorder following allogenic stem cell transplantation for acute lymphoblastic leukaemia: tumor regression after reduction of immunosuppression--a case report. Diagn Pathol 5: 21.
6. Longnecker R (1998) Molecular biology of Epstein-Barr virus. In: McCance D, editor. Human Tumor Viruses. Washington DC: ASM Press. 133-172.
7. Kieff E, Rickinson AB (2007) Epstein-Barr virus and its replication. In: Knipe DM, Howley PM, Griffin DE, Lamb RA, Martin MA, et al., editors. Fields Virology. 5th ed. Philadelphia: Lippincott, Williams & Wilkins. 2603-2654.
8. Joseph AM, Babcock GJ, Thorley-Lawson DA, (2000) EBV persistence involves strict selection of latently infected B cells. Journal of immunology 165: 2975-2981.
9. Babcock GJ, Decker LL, Volk M, Thorley-Lawson DA, (1998) EBV persistence in memory B cells in vivo. Immunity 9: 395-404.
10. Qu L, Rowe DT, (1992) Epstein-Barr virus latent gene expression in uncultured peripheral blood lymphocytes. J Virol 66: 3715-3724.
11. Altmann M, Pich D, Ruiss R, Wang J, Sugden B, et al. (2006) Transcriptional activation by EBV nuclear antigen 1 is essential for the expression of EBV's transforming genes. Proc Natl Acad Sci U S A 103: 14188-14193.
12. Dirmeier U, Neuhierl B, Kilger E, Reisbach G, Sandberg ML, et al. (2003) Latent membrane protein 1 is critical for efficient growth transformation of human B cells by epstein-barr virus. Cancer Res 63: 2982-2989.
13. Kaye KM, Izumi KM, Kieff E, (1993) Epstein-Barr virus latent membrane protein 1 is essential for B-lymphocyte growth transformation. Proc Natl Acad Sci U S A 90: 9150-9154.
14. Kilger E, Kieser A, Baumann M, Hammerschmidt W, (1998) Epstein-Barr virus-mediated B-cell proliferation is dependent upon latent membrane protein 1, which simulates an activated CD40 receptor. EMBO J 17: 1700-1709.
15. Maruo S, Wu Y, Ishikawa S, Kanda T, Iwakiri D, et al. (2006) Epstein-Barr virus nuclear protein EBNA3C is required for cell cycle progression and growth maintenance of lymphoblastoid cells. Proc Natl Acad Sci U S A 103: 19500-19505.
16. Sinclair AJ, Palmero I, Peters G, Farrell PJ, (1994) EBNA-2 and EBNA-LP cooperate to cause G0 to G1 transition during immortalization of resting human B lymphocytes by Epstein-Barr virus. EMBO J 13: 3321-3328.
17. Maruo S, Zhao B, Johannsen E, Kieff E, Zou J, et al. (2011) Epstein-Barr virus nuclear antigens 3C and 3A maintain lymphoblastoid cell growth by repressing p16INK4A and p14ARF expression. Proc Natl Acad Sci U S A 108: 1919-1924.
18. Rickinson AB, Jarvis JE, Crawford DH, Epstein MA, (1974) Observations on the type of infection by Epstein-Barr virus in peripheral lymphoid cells of patients with infectious mononucleosis. Int J Cancer 14: 704-715.
19. Rickinson AB, Finerty S, Epstein MA, (1977) Comparative studies on adult donor lymphocytes infected by EB virus in vivo or in vitro: origin of transformed cells arising in co-cultures with foetal lymphocytes. Int J Cancer 19: 775-782.
20. Kieff E (1996) Epstein-Barr virus and its replication. In: B. Fields DKPH, editor. Fundamental Virology. New York: Raven Press. 1109-1162.
21. Kenney S, Kamine J, Holley-Guthrie E, Lin JC, Mar EC, et al. (1989) The Epstein-Barr virus (EBV) BZLF1 immediate-early gene product differentially affects latent versus productive EBV promoters. J Virol 63: 1729-1736.
22. Feederle R, Kost M, Baumann M, Janz A, Drouet E, et al. (2000) The Epstein-Barr virus lytic program is controlled by the co-operative functions of two transactivators. EMBO J 19: 3080-3089.
23. Grogan E, Jenson H, Countryman J, Heston L, Gradoville L, et al. (1987) Transfection of a rearranged viral DNA fragment, WZhet, stably converts latent Epstein-Barr viral infection to productive infection in lymphoid cells. Proc Natl Acad Sci U S A 84: 1332-1336.
24. Hammerschmidt W, Sugden B, (1988) Identification and characterization of oriLyt, a lytic origin of DNA replication of Epstein-Barr virus. Cell 55: 427-433.
25. Takada K, Shimizu N, Sakuma S, Ono Y, (1986) trans activation of the latent Epstein-Barr virus (EBV) genome after transfection of the EBV DNA fragment. J Virol 57: 1016-1022.
26. Countryman J, Miller G, (1985) Activation of expression of latent Epstein-Barr herpesvirus after gene transfer with a small cloned subfragment of heterogeneous viral DNA. Proc Natl Acad Sci U S A 82: 4085-4089.
27. Gradoville L, Kwa D, El-Guindy A, Miller G, (2002) Protein kinase C-independent activation of the Epstein-Barr virus lytic cycle. J Virol 76: 5612-5626.
28. Laux G, Perricaudet M, Farrell PJ, (1988) A spliced Epstein-Barr virus gene expressed in immortalized lymphocytes is created by circularization of the linear viral genome. EMBO J 7: 769-774.
29. Sample J, Liebowitz D, Kieff E, (1989) Two related Epstein-Barr virus membrane proteins are encoded by separate genes. J Virol 63: 933-937.
30. Beaufils P, Choquet D, Mamoun RZ, Malissen B, (1993) The (YXXL/I)2 signalling motif found in the cytoplasmic segments of the bovine leukaemia virus envelope protein and Epstein-Barr virus latent membrane protein 2A can elicit early and late lymphocyte activation events. EMBO J 12: 5105-5112.
31. Fruehling S, Longnecker R, (1997) The immunoreceptor tyrosine-based activation motif of Epstein-Barr virus LMP2A is essential for blocking BCR-mediated signal transduction. Virology 235: 241-251.
32. Merchant M, Caldwell RG, Longnecker R, (2000) The LMP2A ITAM is essential for providing B cells with development and survival signals in vivo. J Virol 74: 9115-9124.
33. Caldwell RG, Brown RC, Longnecker R, (2000) Epstein-Barr virus LMP2A-induced B-cell survival in two unique classes of EmuLMP2A transgenic mice. J Virol 74: 1101-1113.
34. Caldwell RG, Wilson JB, Anderson SJ, Longnecker R, (1998) Epstein-Barr virus LMP2A drives B cell development and survival in the absence of normal B cell receptor signals. Immunity 9: 405-411.
35. Mancao C, Hammerschmidt W, (2007) Epstein-Barr virus latent membrane protein 2A is a B-cell receptor mimic and essential for B-cell survival. Blood 110: 3715-3721.
36. Miller CL, Lee JH, Kieff E, Longnecker R, (1994) An integral membrane protein (LMP2) blocks reactivation of Epstein-Barr virus from latency following surface immunoglobulin crosslinking. Proc Natl Acad Sci U S A 91: 772-776.
37. Morrison JA, Klingelhutz AJ, Raab-Traub N, (2003) Epstein-Barr virus latent membrane protein 2A activates beta-catenin signaling in epithelial cells. J Virol 77: 12276-12284.
38. Christian SL, Sims PV, Gold MR, (2002) The B cell antigen receptor regulates the transcriptional activator beta-catenin via protein kinase C-mediated inhibition of glycogen synthase kinase-3. Journal of immunology 169: 758-769.
39. Engels N, Yigit G, Emmerich CH, Czesnik D, Schild D, et al. (2012) Epstein-Barr virus LMP2A signaling in statu nascendi mimics a B cell antigen receptor-like activation signal. Cell communication and signaling: CCS 10: 9.
40. Longnecker R, Miller CL, Miao XQ, Tomkinson B, Kieff E, (1993) The last seven transmembrane and carboxy-terminal cytoplasmic domains of Epstein-Barr virus latent membrane protein 2 (LMP2) are dispensable for lymphocyte infection and growth transformation in vitro. J Virol 67: 2006-2013.
41. Longnecker R, Miller CL, Tomkinson B, Miao XQ, Kieff E, (1993) Deletion of DNA encoding the first five transmembrane domains of Epstein-Barr virus latent membrane proteins 2A and 2B. J Virol 67: 5068-5074.
42. Speck P, Kline KA, Cheresh P, Longnecker R, (1999) Epstein-Barr virus lacking latent membrane protein 2 immortalizes B cells with efficiency indistinguishable from that of wild-type virus. J Gen Virol 80 (Pt 8): 2193-2203.
43. Brielmeier M, Mautner J, Laux G, Hammerschmidt W, (1996) The latent membrane protein 2 gene of Epstein-Barr virus is important for efficient B cell immortalization. J Gen Virol 77 (Pt 11): 2807-2818.
44. Scholle F, Bendt KM, Raab-Traub N, (2000) Epstein-Barr virus LMP2A transforms epithelial cells, inhibits cell differentiation, and activates Akt. J Virol 74: 10681-10689.
45. Lynch DT, Zimmerman JS, Rowe DT, (2002) Epstein-Barr virus latent membrane protein 2B (LMP2B) co-localizes with LMP2A in perinuclear regions in transiently transfected cells. J Gen Virol 83: 1025-1035.
46. Lennette ET, Winberg G, Yadav M, Enblad G, Klein G, (1995) Antibodies to LMP2A/2B in EBV-carrying malignancies. European journal of cancer 31A: 1875-1878.
47. Allen MD, Young LS, Dawson CW, (2005) The Epstein-Barr virus-encoded LMP2A and LMP2B proteins promote epithelial cell spreading and motility. J Virol 79: 1789-1802.
48. Rechsteiner MP, Berger C, Zauner L, Sigrist JA, Weber M, et al. (2008) Latent membrane protein 2B regulates susceptibility to induction of lytic Epstein-Barr virus infection. J Virol 82: 1739-1747.
49. Rovedo M, Longnecker R, (2007) Epstein-barr virus latent membrane protein 2B (LMP2B) modulates LMP2A activity. J Virol 81: 84-94.
50. Delecluse HJ, Hilsendegen T, Pich D, Zeidler R, Hammerschmidt W, (1998) Propagation and recovery of intact, infectious Epstein-Barr virus from prokaryotic to human cells. Proc Natl Acad Sci U S A 95: 8245-8250.
51. Altmann M, Hammerschmidt W, (2005) Epstein-Barr virus provides a new paradigm: a requirement for the immediate inhibition of apoptosis. PLoS Biol 3: e404.
52. White RE, Groves IJ, Turro E, Yee J, Kremmer E, et al. (2010) Extensive co-operation between the Epstein-Barr virus EBNA3 proteins in the manipulation of host gene expression and epigenetic chromatin modification. PloS one 5: e13979.
53. Silva R, Moir S, Kardava L, Debell K, Simhadri VR, et al. (2011) CD300a is expressed on human B cells, modulates BCR-mediated signaling, and its expression is down-regulated in HIV infection. Blood 117: 5870-5880.
54. Kardava L, Moir S, Wang W, Ho J, Buckner CM, et al. (2011) Attenuation of HIV-associated human B cell exhaustion by siRNA downregulation of inhibitory receptors. J Clin Invest 121: 2614-2624.
55. Neuhierl B, Feederle R, Hammerschmidt W, Delecluse HJ, (2002) Glycoprotein gp110 of Epstein-Barr virus determines viral tropism and efficiency of infection. Proc Natl Acad Sci U S A 99: 15036-15041.
56. Davies ML, Xu S, Lyons-Weiler J, Rosendorff A, Webber SA, et al. (2010) Cellular factors associated with latency and spontaneous Epstein-Barr virus reactivation in B-lymphoblastoid cell lines. Virology 400: 53-67.
57. Halder S, Murakami M, Verma SC, Kumar P, Yi F, et al. (2009) Early events associated with infection of Epstein-Barr virus infection of primary B-cells. PloS one 4: e7214.
58. Bishop GA, Haxhinasto SA, Stunz LL, Hostager BS, (2003) Antigen-specific B-lymphocyte activation. Critical reviews in immunology 23: 149-197.
59. Lam KP, Kuhn R, Rajewsky K, (1997) In vivo ablation of surface immunoglobulin on mature B cells by inducible gene targeting results in rapid cell death. Cell 90: 1073-1083.
60. Portis T, Ikeda M, Longnecker R, (2004) Epstein-Barr virus LMP2A: regulating cellular ubiquitination processes for maintenance of viral latency? Trends in immunology 25: 422-426.
61. Kalla M, Schmeinck A, Bergbauer M, Pich D, Hammerschmidt W, (2010) AP-1 homolog BZLF1 of Epstein-Barr virus has two essential functions dependent on the epigenetic state of the viral genome. Proc Natl Acad Sci U S A 107: 850-855.
62. Nikitin PA, Yan CM, Forte E, Bocedi A, Tourigny JP, et al. (2010) An ATM/Chk2-mediated DNA damage-responsive signaling pathway suppresses Epstein-Barr virus transformation of primary human B cells. Cell host & microbe 8: 510-522.
63. Takada K, (1984) Cross-linking of cell surface immunoglobulins induces Epstein-Barr virus in Burkitt lymphoma lines. Int J Cancer 33: 27-32.
64. Miller CL, Burkhardt AL, Lee JH, Stealey B, Longnecker R, et al. (1995) Integral membrane protein 2 of Epstein-Barr virus regulates reactivation from latency through dominant negative effects on protein-tyrosine kinases. Immunity 2: 155-166.
65. Portis T, Longnecker R, (2004) Epstein-Barr virus (EBV) LMP2A mediates B-lymphocyte survival through constitutive activation of the Ras/PI3K/Akt pathway. Oncogene 23: 8619-8628.
66. Merino R, Ding L, Veis DJ, Korsmeyer SJ, Nunez G, (1994) Developmental regulation of the Bcl-2 protein and susceptibility to cell death in B lymphocytes. EMBO J 13: 683-691.
67. Grillot DA, Merino R, Pena JC, Fanslow WC, Finkelman FD, et al. (1996) bcl-x exhibits regulated expression during B cell development and activation and modulates lymphocyte survival in transgenic mice. J Exp Med 183: 381-391.
68. Downward J, (1998) Ras signalling and apoptosis. Current opinion in genetics & development 8: 49-54.
69. Wang F, Gregory C, Sample C, Rowe M, Liebowitz D, et al. (1990) Epstein-Barr virus latent membrane protein (LMP1) and nuclear proteins 2 and 3C are effectors of phenotypic changes in B lymphocytes: EBNA-2 and LMP1 cooperatively induce CD23. J Virol 64: 2309-2318.
70. Kintner C, Sugden B, (1981) Identification of antigenic determinants unique to the surfaces of cells transformed by Epstein-Barr virus. Nature 294: 458-460.
71. Patarroyo M, Beatty PG, Nilsson K, Gahmberg CG, (1986) Identification of a cell-surface glycoprotein mediating cell adhesion in EBV-immortalized normal B cells. Int J Cancer 38: 539-547.
72. Rowe M, Hildreth JE, Rickinson AB, Epstein MA, (1982) Monoclonal antibodies to Epstein-Barr virus-induced, transformation-associated cell surface antigens: binding patterns and effect upon virus-specific T-cell cytotoxicity. Int J Cancer 29: 373-381.
73. Thorley-Lawson DA, Mann KP, (1985) Early events in Epstein-Barr virus infection provide a model for B cell activation. J Exp Med 162: 45-59.
74. Miller CL, Longnecker R, Kieff E, (1993) Epstein-Barr virus latent membrane protein 2A blocks calcium mobilization in B lymphocytes. J Virol 67: 3087-3094.